'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Dr Lal Pathlabs has increased 10.49% to Rs 602.6 crore. Operating profit margin has jumped from 26.53% to 28.05%, leading to 16.79% rise in operating profit to Rs 169.00 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 19.97% to 19.55%. Employee cost decreased from 19.33% to 19.15%. Other expenses fell from 34.18% to 33.26%. Selling and administration expenses fell from 13.86% to 12.88%.
Other income rose 40.22% to Rs 25.8 crore. PBIDT rose 19.44% to Rs 194.8 crore. Provision for interest fell 24.24% to Rs 5 crore. Loan funds declined from Rs 246.90 crore as of 31 March 2024 to Rs 157.40 crore as of 31 March 2025. Inventories declined from Rs 37.30 crore as of 31 March 2024 to Rs 36.10 crore as of 31 March 2025. Sundry debtors were higher at Rs 88.10 crore as of 31...
Pleaselogin & subscribe to view the full report.
More Reports
-
(26-Apr-2025)
Shriram Finance
Healthy AUM growth and asset quality, margin declines
-
(26-Apr-2025)
Hindustan Zinc
Expects capex of US$ 225-250 million in FY26
-
(26-Apr-2025)
Atul
NP up 117%
-
(26-Apr-2025)
Reliance Industries
Robust performance in Jio Platforms and Retail
|
|